DrugBiological
PGT121.414.LS clinical trials
- studies test it
- 4
- open now
- 2
- in phase 3
- 0
- first study started
- 2024
Keep track of what changes. Save the PGT121.414.LS studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 4
National Institute of Allergy and Infectious Diseases (NIAID) (3) · HIV Vaccine Trials Network (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses PGT121.414.LS is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 InfectionNot yet recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06987318Written as PGT121.414.LS
- Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1RecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06517693Written as PGT121.414.LS
- The Tatelo Plus StudyActive, not recruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06508749Written as PGT121.414.LS
- Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy ParticipantsSuspendedPhase 1HIV Vaccine Trials NetworkNCT05959707Written as PGT121.414.LS
Given in every arm · 2 — PGT121.414.LS is usual care beside what is tested
- A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV RemissionRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05719441Written as PGT121.414.LS
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04212091Written as PGT121.414.LS